Spyre Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | After market close | – | $-0.36 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | $-0.74 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | – | $-0.15 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | – | $-0.49 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | – | $-0.81 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | $-1.36 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | $-0.86 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | – | – |
Press releases
Announcements Spyre Therapeutics filed with the SEC
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-
Regulation FD disclosure · EX-99.1 to Form 8-K
Disclosures The information contained in this presentation has been
Regulation FD disclosure · EX-99.2 to Form 8-K
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disclosures The information contained in this presentation has been
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
Results of operations · Other events · EX-99.1 to Form 8-K
Disclosures The information contained in this presentation has been
Results of operations · Other events · EX-99.2 to Form 8-K
SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SPY001 Phase 1 Results & Corporate Updates November 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Therapeutics Announces Expected Acceleration of SPY003
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disclosures The information contained in this presentation has been
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of
Material agreement · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Therapeutics Announces $180 Million Private Placement
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Spyre Therapeutics Announces $180 Million Private Placement
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics,
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Other events · EX-99.1 to Form 8-K
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Other events · EX-99.2 to Form 8-K
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Disclosures The information contained in this presentation has been
Regulation FD disclosure · EX-99.1 to Form 8-K
Report of Independent Registered Public Accounting Firm
Executive or director change · Other events · EX-99.1 to Form 8-K
in this presentation has been prepared by Aeglea Biotherapeutics, Inc. and its affiliates, including Spyre Therapeutics, Inc. (“Spyre” or the “Company”) and contains information pertaining to the business and operations of
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows
Executive or director change · Other events · EX-99.1 to Form 8-K
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma
Material agreement · Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K